Sort   by:  
 Page size 
MetabolomicsImidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model
Ferroptosis is a form of regulated cell death that can be induced by inhibition of the cystine-glutamate antiporter, system xc-. Among the existing system xc- inhibitors, imidazole ketone erastin (IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially s...
2019-04-17 | MTBLS774 | MetaboLights
MetabolomicsThe prognostic value of hydroxybutyrate dehydrogenase in diffuse large B-cell lymphoma

In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B-cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). ...

2024-09-02 | MTBLS10446 | MetaboLights
MetabolomicsUntargeted metabolomic analysis in cats with naturally occurring inflammatory bowel disease and alimentary small cell lymphoma
Feline chronic enteropathy (CE) is a common gastrointestinal disorder in cats and mainly comprises inflammatory bowel disease (IBD) and small cell lymphoma (SCL). Differentiation between IBD and SCL can be diagnostically challenging. We characterized the fecal metabolome of 14 healthy cats and 22 ca...
2021-07-13 | MTBLS440 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
MetabolomicsGut Microbiota-Mediated Tryptophan Metabolism Plays Dual Effects in Diffuse Large B-Cell Lymphoma via Regulating 3-IAA/5-HTP Balance and Antitumor Immunity
Timing-dependent tryptophan diets differentially modulate DLBCL outcomes via microbiota-derived 3-IAA (pre-inoculation, anti-tumor) versus 5-HTP (post-inoculation, pro-tumor), with pectin restoring microbial balance to enable a timed tryptophan-pectin precision nutrition strategy for enhanced immuno...
2026-09-07 | MTBLS15570 | MetaboLights
TranscriptomicsDifferential Expression of NF-kB target genes in MALT lymphoma with and without chromosome translocation
MALT lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway. Gastric MALT lymphomas harboring such translocation do not respond to H. pylori eradication, while those without translocation can be...
ORGANISM(S): Homo sapiens 
2010-05-31 | E-GEOD-18736 | biostudies-arrayexpress
ProteomicsRole of BTG1 inactivation in lymphomagenesis and lymphoma dissemination
BTG1 is recurrently mutated in the MCD/C5 subgroup of diffuse large B cell lymphoma (DLBCL), but the functions of this gene in lymphomagenesis have never been investigated so far. Here we provide evidence that Btg1 knock out accelerates the development of a lethal lymphoproliferative disease driven ...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-10 | MSV000089045 | MassIVE
Sort   by:  
 Page size